(1996-2017)
Brief History. The Quebec IBD Genetics Consortium (QIGC) has its origins (1996-2002) in a group of five academic clinical centers that collected DNA samples and clinical information for IBD genetics projects. In 2002, it played an integral part in the creation of the North American IBD Genetics Consortium (IBDGC), which was constituted by six different centers across Canada and the USA.
Mission. The purpose of the QIGC has been to discover and examine the influence of genetic variables on IBD in the Quebec population and to collaborate internationally to have an impact on IBD worldwide. The objective is to translate these genetic discoveries in to better understanding of the pathogenesis of IBD and to fulfill the mission of improving the diagnostic, as well as preventative and management strategies for these chronic inflammatory diseases.
Consortium members. Here are the members of the QIGC:
| John D. Rioux, PhD (Leader) Whitehead/MIT Center for Genome Research Institut de cardiologie de Montréal, Université de Montréal | Alain Bitton, MD (Co-Leader) Royal Victoria Hospital McGill University |
| Guy Aumais, MD Hôpital Maisonneuve-Rosemont Université de Montréal | Gilles Jobin, MD Hôpital Maisonneuve-Rosemont Université de Montréal |
| Edmond-Jean Bernard, MD Hôpital Hôtel Dieu Université de Montréal | Raymond G. Lahaie, MD Hôpital Saint-Luc Université de Montréal |
| Albert Cohen, MD Jewish General Hospital McGill University | Diane Langelier, MD Hôpital Fleurimont Université de Sherbrooke |
| Colette Deslandres, MD Hôpital Sainte-Justine Université de Montréal | Pierre Paré, MD CHAUQ – Hôpital St – Sacrement Université Laval |
| Sylviane Forget, MD Montreal Children’s Hospital McGill University | Ernest G. Seidman, MD Hôpital Sainte-Justine Université de Montréal |
| Daniel Gaudet, MD Complexe hospitalier de la Sagamie & Université de Montréal | Gary E. Wild, MD Montreal General Hospital McGill University |